{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:04:02Z","timestamp":1784689442354,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007558","name":"Rutgers Cancer Institute of New Jersey","doi-asserted-by":"publisher","award":["P30CA072720"],"award-info":[{"award-number":["P30CA072720"]}],"id":[{"id":"10.13039\/100007558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eururo.2025.09.4173","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T22:42:52Z","timestamp":1760654572000},"page":"29-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Future of Bladder Preservation for Muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"89","author":[{"given":"Melinda Z.","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saum","family":"Ghodoussipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8397-7797","authenticated-orcid":false,"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.09.4173_b0005","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2025.09.4173_b0010","doi-asserted-by":"crossref","unstructured":"Gupta S, Hensley PJ, Li R, et al. Bladder preservation strategies in muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. Eur Urol 2026;89:18\u201328.","DOI":"10.1016\/j.eururo.2025.03.017"},{"key":"10.1016\/j.eururo.2025.09.4173_b0015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.urolonc.2025.01.012","article-title":"Trimodality therapy versus radical cystectomy for muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"43","author":"Fong","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.09.4173_b0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE \u2014 a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.09.4173_b0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.09.4173_b0030","doi-asserted-by":"crossref","unstructured":"Rezaee ME, Mahon KM, Su ZT, et al. Characterizing symptoms and defining toxicity in ambulatory transurethral resection of bladder tumor: results from a multicenter prospective cohort study. Urology. In press. https:\/\/doi.org\/10.1016\/j.urology.2025.06.051.","DOI":"10.1016\/j.urology.2025.06.051"},{"key":"10.1016\/j.eururo.2025.09.4173_b0035","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3390\/cancers16142561","article-title":"Sequential endoluminal gemcitabine and cabazitaxel with intravenous pembrolizumab as a bladder-preserving strategy for docetaxel-unresponsive non-muscle invasive urothelial carcinoma following transurethral resection of bladder tumor","volume":"16","author":"McElree","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2025.09.4173_b0040","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.23.02510","article-title":"Bladder-preserving trimodality treatment for high-grade t1 bladder cancer: results from phase II protocol NRG Oncology\/RTOG 0926","volume":"42","author":"Dahl","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.4173_b0045","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1186\/s12885-023-11605-8","article-title":"Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer","volume":"23","author":"Gore","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2025.09.4173_b0050","doi-asserted-by":"crossref","unstructured":"Necchi A, Galsky MD, Dizman N, et al. End points for the next-generation bladder-sparing perioperative trials for patients with muscle-invasive bladder cancer. J Clin Oncol. In press. https:\/\/doi.org\/10.1200\/jco-25-01608.","DOI":"10.1200\/JCO-25-01608"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825047347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825047347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:04:09Z","timestamp":1773875049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825047347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0302283825047347"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4173","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Future of Bladder Preservation for Muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}